Actelion Ltd. lost almost one-quarter of its value Monday following news that it halted a Phase III trial of its drug for acute heart failure, Veletri, after an interim analysis indicated that it would fail to attain its primary endpoints. (BioWorld International)
Actelion Ltd. lost almost one-quarter of its value Monday following news that it halted a Phase III trial of its drug for acute heart failure, Veletri, after an interim analysis indicated that it would fail to attain its primary endpoints. (BioWorld International)
Arpida Ltd. acquired its erstwhile partner Combio A/S in an all-stock transaction that will boost its chemistry capabilities and expand its head count from 47 to 73 employees. (BioWorld International)
